Overcoming acquired resistance to targeted therapies in lung cancer

At the European Cancer Congress (ECC) 2015, David Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, Aurora, CO, explains that strategies to manage progression in patients with non-small cell lung cancer (NSCLC) should be tailored to individual patients, as there may be a need to address pharmacologic issues or the molecular emergence of new resistant clones.

Year of Production:
Running Time:
Color/Sound:

2015
02:25
Color/Sound

Comments are closed.